AGTR1 and Myocardial fibrosis: Thus, combined administration of these two RAS protective agonists could be necessary in association with AT1 receptor blockade to better control myocardial fibrosis and hypertrophy, as also demonstrated in different organs of different experimental models [16,17,33].